Product Description

Known For: One of Alabama’s largest and most established psychiatric practices — offering Spravato alongside TMS and Vagal Nerve Stimulation under a full team of 20+ psychiatrists, 20+ nurse practitioners, and 40+ psychologists with hospital affiliations at 7 Alabama facilities.

HealingMaps Take: Grayson & Associates is the institutional anchor of Birmingham psychiatric care. Founded by Dr. Garry Grayson decades ago, the practice has grown into one of Alabama’s largest mental health groups, with 20+ psychiatrists, 20+ nurse practitioners, nearly 40 psychologists, and over 20 licensed counselors spread across multiple Birmingham-area locations. Their clinicians hold privileges at seven Alabama hospitals, which is a marker of clinical rigor and community integration that standalone ketamine clinics simply can’t match. For patients with treatment-resistant depression, Dr. Armand Schachter at the Galleria location specializes in the interventional psychiatric suite — Spravato, TMS, and Vagal Nerve Stimulation — giving patients multiple evidence-based options if one modality doesn’t produce the desired response. The scale of the practice also means patients benefit from integrated care: a single intake can lead to psychiatry, therapy, Spravato, TMS, or medication management depending on what’s clinically indicated. Insurance coverage is a major plus — most major plans are accepted, which is increasingly rare in the interventional psychiatry space. For Birmingham patients who want Spravato or TMS inside a traditional, insurance-friendly psychiatric medical home, Grayson is the default choice.

Patient Review

“Grayson is where Birmingham psychiatrists send the patients they can’t help. The team does not market themselves as a ketamine clinic — they are a full psychiatric practice, and Spravato is one tool among many. That matters, because Dr. Schachter spent months adjusting my medications before recommending Spravato, which ended up working.”

About Grayson & Associates

Grayson & Associates is one of Alabama’s largest and most established psychiatric practices, headquartered at 2200 Lakeshore Drive, Suite 150, Birmingham, AL 35209. The Lakeshore flagship is one of several Birmingham-area locations. The practice offers Spravato (esketamine), Transcranial Magnetic Stimulation (TMS), Vagal Nerve Stimulation, psychiatric medication management, and psychotherapy. Interventional psychiatry for treatment-resistant depression is led by Dr. Armand Schachter at the Galleria location. With 20+ psychiatrists, 20+ nurse practitioners, nearly 40 psychologists, and 20+ licensed counselors on staff across multiple locations, Grayson clinicians also hold privileges at seven Alabama hospitals.

For more on how ketamine therapy works, see our complete guide to ketamine therapy.

What People Like

One of Alabama’s largest psychiatric practices with 80+ total clinicians. Spravato offered alongside TMS and Vagal Nerve Stimulation for treatment-resistant depression. Accepts most major insurance plans — unusual in interventional psychiatry. Hospital privileges at 7 Alabama facilities signal clinical rigor. Multiple Birmingham-area locations (Lakeshore, Park Plaza, Homewood, Galleria). Integrated care model — single intake can lead to any service.

What People Don’t Like

No IV ketamine option — Spravato only for ketamine-class treatment. No KAP or psychotherapy-during-treatment model. Large practice size may feel less personalized than boutique clinics. Pricing not published — depends heavily on insurance plan. Interventional psychiatry (Spravato/TMS/VNS) concentrated with specific clinicians, not all offices.

Getting Started at Grayson & Associates

Call (205) 871-6926 or visit grayson.associates to schedule an initial psychiatric evaluation. Birmingham flagship location: 2200 Lakeshore Dr, Suite 150, Birmingham, AL 35209. Request Dr. Armand Schachter at the Galleria location if specifically interested in Spravato, TMS, or Vagal Nerve Stimulation for treatment-resistant depression.

Learn more about the evidence behind ketamine for depression at the National Institute of Mental Health.